A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke

International Journal of Stroke

Volumn 5, Issue 5, 2010, Pages 385-394

  de Lau, Lonneke M L ^a   Leebeek, Frank W G ^a   de Maat, Moniek P M ^a   Koudstaal, Peter J ^a   Dippel, Diederik W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coagulation; Haemostasis; Interaction; Risk factors; Stroke; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; FATTY ACID BINDING PROTEIN; FIBRINOGEN; HOMOCYSTEINE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; VON WILLEBRAND FACTOR;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; DISEASE ASSOCIATION; FIBRINOGEN BLOOD LEVEL; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; ORAL CONTRACEPTION; PATENT FORAMEN OVALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION DISORDERS, INHERITED; CHILD; HUMANS; RISK FACTORS; STROKE;

EID: 77956233907     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2010.00468.x     Document Type: Review

References (117)

1. Allen CL, Bayraktutan U. Risk factors for ischaemic stroke. Int J Stroke 2008, 3:105-16.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008, 371:1612-23.
3. Guercini F, Acciarresi M, Agnelli G, Paciaroni M. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 2008, 6:549-54.
4. Rahemtullah A, Van Cott EM. Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 2007, 131:890-901.
5. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001, 32:1793-9.
6. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000, 31:3067-78.
7. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007, 98:530-42.
8. Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost 2007, 33:588-96.
9. Camerlingo M, Finazzi G, Casto L, Laffranchi C, Barbui T, Mamoli A. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology 1991, 41:1371-3.
10. Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke 1990, 21:1077-80.
11. Folsom AR, Rosamond WD, Shahar E. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999, 100:736-42.
12. Knuiman MW, Folsom AR, Chambless LE, Liao D, Wu KK. Association of hemostatic variables with MRI-detected cerebral abnormalities: the atherosclerosis risk in communities study. Neuroepidemiology 2001, 20:96-104.
13. Strater R, Becker S, von Eckardstein A. Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study. Lancet 2002, 360:1540-5.
14. Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch Dis Child 2005, 90:402-5.
15. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984, 311:1525-8.
16. Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology 1992, 42:1029-33.
17. Barinagarrementeria F, Cantu-Brito C, De La Pena A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study. Stroke 1994, 25:287-90.
18. Bertina RM, Koeleman BP, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-7.
19. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003, 146:948-57.
20. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002, 100:3-10.
21. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004, 61:1652-61.
22. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995, 332:912-7.
23. Cushman M, Rosendaal FR, Psaty BM. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998, 79:912-5.
24. Kenet G, Sadetzki S, Murad H. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000, 31:1283-8.
25. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008, 112:19-27.
26. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999, 99:999-1004.
27. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost 2002, 87:614-21.
28. Vasse M. Protein Z, a protein seeking a pathology. Thromb Haemost 2008, 100:548-56.
29. Yin ZF, Huang ZF, Cui J. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA 2000, 97:6734-8.
30. van Goor MP, Dippel DW, Jie KS, de Maat MP, Koudstaal PJ, Leebeek FW. Low protein Z levels but not the protein Z gene G79A polymorphism are a risk factor for ischemic stroke. Thromb Res 2008, 123:213-8.
31. Vasse M, Guegan-Massardier E, Borg JY, Woimant F, Soria C. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 2001, 357:933-4.
32. Kobelt K, Biasiutti FD, Mattle HP, Lammle B, Wuillemin WA. Protein Z in ischaemic stroke. Br J Haematol 2001, 114:169-73.
33. McQuillan AM, Eikelboom JW, Hankey GJ. Protein Z in ischemic stroke and its etiologic subtypes. Stroke 2003, 34:2415-9.
34. Staton J, Sayer M, Hankey GJ, Cole V, Thom J, Eikelboom JW. Protein Z gene polymorphisms, protein Z concentrations, and ischemic stroke. Stroke 2005, 36:1123-7.
35. Lopaciuk S, Bykowska K, Kwiecinski H. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost 2001, 7:346-50.
36. Refaai MA, Ahn C, Lu L, Wu K, Broze GJ. Protein Z and ZPI levels and cardiovascular events. J Thromb Haemost 2006, 4:1628-9.
37. Santacroce R, Cappucci F, Di Perna P, Sessa F, Margaglione M. Protein Z gene polymorphisms are associated with protein Z plasma levels. J Thromb Haemost 2004, 2:1197-9.
38. Lim W, Crowther MA. Antiphospholipid antibiodies: a critical review of the literature. Curr Opin Hematol 2007, 14:494-9.
39. Miyakis S, Lockshin MD, Atsumi T. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
40. Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005, 357:17-33.
41. Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008, 6:399-401.
42. Tuhrim S, Rand JH, Wu XX. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999, 30:1561-5.
43. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992, 23:189-93.
44. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009, 8:998-1005.
45. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke 2000, 31:1289-93.
46. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992, 339:451-3.
47. Ginsburg KS, Liang MH, Newcomer L. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997-1002.
48. Brey RL, Abbott RD, Curb JD. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001, 32:1701-6.
49. Levine SR, Brey RL, Tilley BC. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-84.
50. Janardhan V, Wolf PA, Kase CS. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004, 35:736-41.
51. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005, 20:105-12.
52. Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin 2003, 21:167-92.
53. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985, 64:16-35.
54. Lindvig K, Moller H, Mosbech J, Jensen OM. The pattern of cancer in a large cohort of stroke patients. Int J Epidemiol 1990, 19:498-504.
55. Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM. Stroke in patients with cancer: incidence and etiology. Neurology 2004, 62:2025-30.
56. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002, 4:465-73.
57. Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2008, 119:1-16.
58. Zhang YY, Cordato D, Shen Q, Sheng AZ, Hung WT, Chan DK. Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study. Cerebrovasc Dis 2007, 23:181-7.
59. Taccone FS, Jeangette SM, Blecic SA. First-ever stroke as initial presentation of systemic cancer. J Stroke Cerebrovasc Dis 2008, 17:169-74.
60. Lonn E. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction? Curr Opin Hematol 2007, 14:481-7.
61. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006, 48:914-23.
62. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007, 6:830-8.
63. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-22.
64. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202-8.
65. Hankey GJ. Is plasma homocysteine a modifiable risk factor for stroke? Nat Clin Pract Neurol 2006, 2:26-33.
66. Lonn E, Yusuf S, Arnold MJ. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-77.
67. Toole JF, Malinow MR, Chambless LE. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-75.
68. Bonaa KH, Njolstad I, Ueland PM. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-88.
69. Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord 2008, 8:24-37.
70. Spence JD. Homocysteine and stroke prevention: have the trials settled the issue? Int J Stroke 2006, 1:242-4.
71. Wang X, Qin X, Demirtas H. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007, 369:1876-82.
72. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006, 296:2720-6.
73. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006, 4:1186-93.
74. Bongers TN, de Maat MP, van Goor ML. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006, 37:2672-7.
75. Bongers TN, de Bruijne EL, Dippel DW, de Jong AJ, Deckers JW, Poldermans D, de Matt MP, Leebeek FW. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009, 207:250-4.
76. Meloni G, Proia A, Antonini G. Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation. Haematologica 2001, 86:1194-9.
77. Dervenoulas J, Tsirigotis P, Bollas G. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 2000, 79:66-72.
78. Gruber O, Wittig L, Wiggins CJ, von Cramon DY. Thrombotic thrombocytopenic purpura: MRI demonstration of persistent small cerebral infarcts after clinical recovery. Neuroradiology 2000, 42:616-8.
79. Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher 2004, 19:86-9.
80. Scheid R, Hegenbart U, Ballaschke O, Von Cramon DY. Major stroke in thrombotic-thrombocytopenic purpura (Moschcowitz syndrome). Cerebrovasc Dis 2004, 18:83-5.
81. Oksala NK, Heikkinen M, Mikkelsson J. Smoking and the platelet fibrinogen receptor glycoprotein IIb/IIIA PlA1/A2 polymorphism interact in the risk of lacunar stroke and midterm survival. Stroke 2007, 38:50-5.
82. Zee RY, Michaud SE, Diehl KA. Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis 2008, 197:694-9.
83. van Goor ML, Gomez Garcia E, Brouwers GJ, Leebeek FW, Koudstaal PJ, Dippel DW. PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke. Thromb Res 2002, 108:63-5.
84. Danesh J, Lewington S, Thompson SG. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-809.
85. Rothwell PM, Howard SC, Power DA. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004, 35:2300-5.
86. Hankey GJ, Algra A, Chen C. VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke 2007, 2:144-50.
87. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000, 95:586-91.
88. Reiner AP, Frank MB, Schwartz SM. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002, 116:376-82.
89. Pruissen DM, Slooter AJ, Rosendaal FR, van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008, 111:1282-6.
90. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007, 14:242-8.
91. Guimaraes AH, de Bruijne EL, Lisman T. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009, 145:115-20.
92. Leebeek FW, Goor MP, Guimaraes AH. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005, 3:2211-8.
93. Santamaria A, Oliver A, Borrell M. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003, 34:2387-91.
94. de Bruijne EL, Gils A, Guimaraes AH. The role of thrombin activatable fibrinolysis inhibitor (TAFI) in arterial thrombosis at young age: the ATTAC study. J Thromb Haemost 2009
95. Attia J, Thakkinstian A, Wang Y. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis 2007, 16:173-9.
96. van Goor ML, Garcia EG, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost 2005, 93:92-6.
97. Desai AJ, Fuller CJ, Jesurum JT, Reisman M. Patent foramen ovale and cerebrovascular diseases. Nat Clin Pract Cardiovasc Med 2006, 3:446-55.
98. Lechat P, Mas JL, Lascault G. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318:1148-52.
99. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000, 55:1172-9.
100. Mas JL, Arquizan C, Lamy C. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740-6.
101. Pezzini A, Del Zotto E, Magoni M. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003, 34:28-33.
102. Lichy C, Reuner KH, Buggle F. Prothrombin G20210A mutation, but not factor V Leiden, is a risk factor in patients with persistent foramen ovale and otherwise unexplained cerebral ischemia. Cerebrovasc Dis 2003, 16:83-7.
103. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 2007, 38:2070-3.
104. Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 2003, 14:261-8.
105. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000, 284:72-8.
106. Aznar J, Mira Y, Vaya A. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost 2004, 91:1031-4.
107. Pezzini A, Grassi M, Iacoviello L. Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry 2007, 78:271-6.
108. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006, 91:844-7.
109. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005, 3:1213-7.
110. Rosing J, Middeldorp S, Curvers J. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999, 354:2036-40.
111. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost 2007, 5((Suppl. 1)):270-5.
112. Prandoni P, Bilora F, Marchiori A. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003, 348:1435-41.
113. Reich LM, Folsom AR, Key NS. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006, 4:1909-13.
114. van der Hagen PB, Folsom AR, Jenny NS. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006, 4:1903-8.
115. U-King-Im JM, Tang T, Moustafa RR, Baron JC, Warburton EA, Gillard JH. Imaging the cellular biology of the carotid plaque. Int J Stroke 2007, 2:85-96.
116. de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007, 44:106-13.
117. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients? why, how, and when. Stroke 2009, 40:1549-52.